Skip to content

Antithrombotic therapy in ischemic heart disease

TL;DR — Antithrombotic treatment prevents arterial thrombosis but creates bleeding risk that accumulates with drug number, potency, and duration. Aspirin is foundational in secondary prevention; after ACS or PCI, dual antiplatelet therapy (DAPT) is the default initial strategy, then duration and agent are individualized (ATT 2009, PMID 19482214; Byrne 2023, PMID 37622654). TWILIGHT showed that dropping aspirin after 3 months and continuing ticagrelor reduced bleeding without increasing ischemic events in selected high-risk PCI patients, and MASTER DAPT supported abbreviated therapy in high-bleeding-risk patients (Mehran 2019, PMID 31556978; Valgimigli 2021, PMID 34449185). Conversely, prolonged DAPT reduced stent thrombosis and MI but increased bleeding in the primary DAPT Study report (Mauri 2014, PMID 25399658). In stable atherosclerotic disease, low-dose rivaroxaban plus aspirin reduced MACE and mortality but increased major bleeding in COMPASS (Eikelboom 2017, PMID 28844192). The correct question is not “short or long DAPT?” but “what is this patient's evolving ischemic-to-bleeding balance, and is there a continuing indication for every agent?”

Mechanistic map

Drug axis Target Main use in IHD Principal harm
Aspirin COX-1/thromboxane ACS and long-term secondary prevention GI/intracranial bleeding
Clopidogrel P2Y12 DAPT, aspirin alternative, chronic therapy Variable response; bleeding
Prasugrel P2Y12 PCI-treated ACS Bleeding; contraindications/age-weight cautions
Ticagrelor P2Y12 ACS and selected monotherapy strategies Bleeding, dyspnea, bradyarrhythmia
Parenteral anticoagulant Thrombin/Xa pathway Acute ACS/PCI Bleeding; dosing errors in CKD/weight
Low-dose rivaroxaban Xa Selected stable CAD/PAD with aspirin Major bleeding
Full-dose oral anticoagulant Xa or thrombin/VKA AF, VTE, mechanical valve contexts Major bleeding; interaction with antiplatelets

Antiplatelet and anticoagulant therapies are not interchangeable: coronary platelet-rich thrombosis and cardioembolic thrombosis involve overlapping but distinct pathways.

Aspirin in secondary prevention

The ATT individual-participant meta-analysis found that in secondary prevention, aspirin produced a large absolute reduction in serious vascular events compared with control, while increasing major extracranial bleeding (ATT 2009, PMID 19482214). The balance differs in primary prevention and should not be imported into established IHD.

Long-term aspirin is usual after MI or revascularization unless bleeding, allergy, or an alternative antithrombotic strategy changes the balance (Virani 2023, PMID 37471501).

DAPT after ACS and PCI

Default ACS treatment combines aspirin with a P2Y12 inhibitor, with potency and pretreatment tied to diagnosis and invasive strategy (Byrne 2023, PMID 37622654; Rao 2025, PMID 40014670).

Factor favoring more ischemic protection Factor favoring shorter/less intense therapy
Prior stent thrombosis or recurrent MI Prior intracranial hemorrhage
Complex or multiple stents Active/recent major bleeding
Diabetes, CKD, diffuse multivessel disease Severe anemia/thrombocytopenia
ACS presentation Need for long-term anticoagulation
Tolerated DAPT without bleeding Frailty, falls, advanced age, low weight

These columns overlap: CKD and age increase both ischemia and bleeding. Scores can structure discussion but do not eliminate judgment.

Evidence for shortening and aspirin withdrawal

TWILIGHT enrolled high-risk patients who tolerated 3 months of DAPT after PCI, then randomized ticagrelor plus aspirin versus ticagrelor plus placebo. Ticagrelor monotherapy reduced BARC 2/3/5 bleeding (4.0% vs 7.1%; HR 0.56) without an increase in death, MI, or stroke (Mehran 2019, PMID 31556978).

The result applies to selected, event-free, adherent patients on ticagrelor; it is not proof that aspirin can be dropped immediately after every PCI. Prespecified analyses found consistent signals in prior MI and complex PCI subgroups (Chiarito 2022, PMID 35033468; Dangas 2020, PMID 32240761).

MASTER DAPT randomized high-bleeding-risk patients after one month of DAPT. Abbreviated therapy was noninferior for net adverse clinical and major adverse cardiac/cerebral events and reduced major or clinically relevant nonmajor bleeding (Valgimigli 2021, PMID 34449185).

Evidence for extension

The DAPT Study compared 30 versus 12 months after drug-eluting stents: extended thienopyridine reduced stent thrombosis (0.4% vs 1.4%; HR 0.29, 95% CI 0.17–0.48) and MI (2.1% vs 4.1%; HR 0.47) but increased moderate/severe bleeding (2.5% vs 1.6%) and showed higher all-cause death (2.0% vs 1.5%; HR 1.36, 95% CI 1.00–1.85; P=0.05), illustrating benefit and harm from the same biological intensification (Mauri 2014, PMID 25399658).

Strategy Expected gain Expected cost
Short DAPT then single agent Less bleeding Possible early ischemic/stent risk if poorly selected
Standard-duration DAPT Broad evidence after ACS/PCI Continued cumulative bleeding
Extended DAPT Fewer stent thromboses/spontaneous MI in selected patients More major bleeding
P2Y12 monotherapy Preserves potent platelet inhibition, removes aspirin Evidence is agent/population specific

Dual-pathway inhibition in chronic disease

COMPASS randomized stable CAD/PAD patients to rivaroxaban 2.5 mg twice daily plus aspirin, rivaroxaban 5 mg twice daily, or aspirin. The combination reduced cardiovascular death, stroke, or MI (HR 0.76) and all-cause death (HR 0.82), while increasing major bleeding (HR 1.70); fatal or intracranial bleeding was not significantly increased (Eikelboom 2017, PMID 28844192).

This strategy is for selected high-ischemic/acceptable-bleeding-risk patients, not for those with an indication for full-dose anticoagulation or high bleeding risk.

Patients needing oral anticoagulation

AF plus ACS/PCI creates a three-drug problem. Prolonged triple therapy markedly increases bleeding; contemporary pathways favor the shortest necessary aspirin exposure followed by an oral anticoagulant plus one P2Y12 inhibitor, then anticoagulant alone when coronary risk permits (Rao 2025, PMID 40014670).

Question Required information
Why anticoagulation? AF stroke prevention, VTE, mechanical valve, other
How recent/complex is PCI? Stent thrombosis hazard is front-loaded
Which P2Y12 agent? Evidence and bleeding differ; clopidogrel commonly paired
Renal function/weight/age? Determines dose and exposure
Gastroprotection? PPI can reduce upper-GI risk in appropriate patients

Bleeding is an outcome, not a nuisance endpoint

Major bleeding predicts subsequent death and MI, can trigger transfusion or treatment interruption, and often carries long-term disability. Comparisons should report site, severity, fatality, transfusion, and intracranial events rather than one aggregate label (Chew 2020, PMID 32646566).

Preventive controls include radial access, correct renal/weight dosing, avoidance of unnecessary NSAIDs, review of interacting drugs, treatment of anemia/GI lesions, PPI when indicated, and explicit stop dates.

Perioperative and interruption decisions

The risk of stopping therapy is highest soon after ACS or stenting, while the risk of continuing depends on procedure bleeding consequences. Decisions require the exact stent/ACS date, agent half-life, urgency, and whether aspirin can continue. Bridging is not a generic replacement for antiplatelet therapy.

Antithrombotic review timepoints

Timepoint Mandatory questions
Before PCI Is this ACS? Is chronic anticoagulation present? What is bleeding history?
At discharge Which agents, doses, indication, and planned stop/review dates?
1 month Bleeding, adherence, renal function, anemia, early ischemic events?
3 months Is aspirin withdrawal supported by the patient's strategy and trial phenotype?
6–12 months Does continuing DAPT provide net benefit?
After any bleed Cause treated? Therapy temporarily held or permanently changed?
Before surgery Exact PCI date, urgency, procedure bleeding consequence, restart plan?
Annually in chronic CAD Is every antithrombotic still indicated? Has risk changed?

Net-benefit reporting

Report separately Why
Cardiovascular death Not equivalent to revascularization
Spontaneous MI More prognostically important than many procedural enzyme rises
Stent thrombosis Rare, catastrophic, treatment-specific
Intracranial/fatal bleeding Highest-consequence harm
GI bleeding/transfusion Common, preventable, adherence-disrupting
Net composite Useful only after components are visible

This format prevents a favorable “net clinical outcome” from hiding a mortality-neutral trade of common bleeding against softer ischemic endpoints (Chew 2020, PMID 32646566).

Comparative antiplatelet evidence beyond duration alone

Trial/strategy Population and result Interpretation boundary
CAPRIE Among 19,185 patients with prior MI, stroke, or PAD, annual ischemic stroke/MI/vascular death was 5.32% with clopidogrel versus 5.83% with aspirin, an 8.7% relative reduction (95% CI 0.3%–16.5%) (CAPRIE 1996, PMID 8918275). The absolute difference was about 0.51 percentage points/year and the population was broader than coronary disease alone.
TRITON–TIMI 38 In 13,608 PCI-planned ACS patients, prasugrel reduced CV death/MI/stroke from 12.1% to 9.9% (HR 0.81, 95% CI 0.73–0.90) but increased major bleeding from 1.8% to 2.4% (HR 1.32, 95% CI 1.03–1.68) (Wiviott 2007, PMID 17982182). Potency trades ischemia for bleeding; prior stroke/TIA, age, and weight modify suitability.
PLATO In 18,624 ACS patients, ticagrelor reduced CV death/MI/stroke from 11.7% to 9.8% (HR 0.84, 95% CI 0.77–0.92); overall major bleeding was similar, while non-CABG major bleeding was higher (Wallentin 2009, PMID 19717846). “No increase in overall major bleeding” does not mean no bleeding redistribution or tolerability burden.
GLOBAL LEADERS One month of DAPT followed by ticagrelor alone did not significantly reduce death/new Q-wave MI at 2 years (3.81% vs 4.37%; RR 0.87, 95% CI 0.75–1.01) and did not reduce BARC 3/5 bleeding (Vranckx 2018, PMID 30166073). Positive aspirin-withdrawal trials are design- and population-specific.
HOST-EXAM Event-free patients 6–18 months after DES were randomized to chronic clopidogrel or aspirin; clopidogrel reduced the composite of death, MI, stroke, ACS readmission, or major bleeding (Koo 2021, PMID 34010616). These open-label Korean maintenance data do not describe the early post-ACS period.
COMPASS Rivaroxaban 2.5 mg twice daily plus aspirin reduced CV death/stroke/MI (HR 0.76) but increased major bleeding (HR 1.70) in stable CAD/PAD (Eikelboom 2017, PMID 28844192). Dual-pathway inhibition is not extended DAPT and is inappropriate when full-dose anticoagulation is indicated.

Trials supporting aspirin withdrawal generally randomize only patients who reached a post-PCI landmark without early ischemia, major bleeding, or nonadherence. TWILIGHT's prior-MI and complex-PCI analyses support consistency within that selected frame, whereas GLOBAL LEADERS failed its superiority endpoint in a broader design (Dangas 2020, PMID 32240761; Chiarito 2022, PMID 35033468; Vranckx 2018, PMID 30166073). Conversely, extended DAPT reduces spontaneous MI and stent thrombosis at a bleeding cost, so calendar duration alone cannot identify net benefit (Mauri 2014, PMID 25399658). Guidelines consequently emphasize repeated ischemic/bleeding reassessment (Virani 2023, PMID 37471501; Byrne 2023, PMID 37622654; Rao 2025, PMID 40014670).

Bleeding definitions are a source of apparent disagreement: TIMI, GUSTO, ISTH, and BARC capture different severities and sites. Comparisons should expose intracranial/fatal bleeding and transfusion separately (Chew 2020, PMID 32646566). ATT supplies the long-run aspirin anchor but cannot settle modern post-DES sequencing among clopidogrel, ticagrelor, abbreviated DAPT, or low-dose anticoagulation (ATT 2009, PMID 19482214).

The historical efficacy/bleeding exchange is visible in CURE: adding clopidogrel to aspirin reduced CV death/MI/stroke from 11.4% to 9.3% (RR 0.80, 95% CI 0.72–0.90) but increased major bleeding from 2.7% to 3.7% (RR 1.38) (CURE 2001, PMID 11519503). In stable survivors 1–3 years after MI, PEGASUS ticagrelor 60 mg reduced CV death/MI/stroke from 9.04% to 7.77% at three years (HR 0.84, 95% CI 0.74–0.95) while TIMI major bleeding rose from 1.06% to 2.30% (Bonaca 2015, PMID 25773268).

AF-PCI trials consistently show the bleeding price of triple therapy. WOEST reported bleeding in 19.4% with oral anticoagulant plus clopidogrel versus 44.4% when aspirin was added (HR 0.36, 95% CI 0.26–0.50) (Dewilde 2013, PMID 23415013). PIONEER AF-PCI found clinically significant bleeding of 16.8% and 18.0% with two rivaroxaban strategies versus 26.7% with VKA triple therapy (HR 0.59 and 0.63 versus control) (Gibson 2016, PMID 27959713). RE-DUAL PCI similarly reduced major/clinically relevant bleeding with dabigatran dual therapy (110-mg HR 0.52, 95% CI 0.42–0.63; 150-mg HR 0.72, 95% CI 0.58–0.88) (Cannon 2017, PMID 28844193). In AUGUSTUS, apixaban reduced bleeding versus VKA (HR 0.69, 95% CI 0.58–0.81), whereas aspirin nearly doubled bleeding versus placebo (HR 1.89, 95% CI 1.59–2.24) (Lopes 2019, PMID 30883055). ENTRUST-AF PCI established noninferiority, not superiority, of edoxaban dual therapy for bleeding (HR 0.83, 95% CI 0.65–1.05) (Vranckx 2019, PMID 31492505). These trials were not powered to exclude small ischemic differences, so “less bleeding” does not mean aspirin has no early role.

Very-short DAPT evidence is likewise population-bound. STOPDAPT-2 found the net composite at one year in 2.36% versus 3.70% (HR 0.64, 95% CI 0.42–0.98) with one-month DAPT then clopidogrel, driven by less bleeding in a Japanese population (Watanabe 2019, PMID 31237644). SMART-CHOICE found three-month DAPT then P2Y12 monotherapy noninferior for death/MI/stroke (2.9% vs 2.5%) with less BARC 2–5 bleeding (HR 0.58, 95% CI 0.36–0.92) (Hahn 2019, PMID 31237645). Ethnicity, ACS proportion, agent, stent, adherence, and noninferiority margins constrain transportability.

Agent choice is as conditional as duration

Evidence after the DAPT period challenges automatic lifelong aspirin. Among 4,717 event-free HOST-EXAM Extended participants analyzed per protocol, clopidogrel reduced the 5.8-year composite net outcome versus aspirin (12.8% vs 16.9%; HR 0.74, 95% CI 0.63–0.86), with lower thrombotic (7.9% vs 11.9%; HR 0.66, 95% CI 0.55–0.79) and BARC ≥2 bleeding outcomes (4.5% vs 6.1%; HR 0.74, 95% CI 0.57–0.94), but no mortality difference; conditioning on a year free of events and the East Asian setting limit transportability (Kang 2023, PMID 36342475).

After ACS PCI, TICO found that ticagrelor monotherapy after 3 months of DAPT reduced the 1-year net composite from 5.9% to 3.9% (HR 0.66, 95% CI 0.48–0.92), driven by less major bleeding (1.7% vs 3.0%; HR 0.56, 95% CI 0.34–0.91), while ischemic events alone were not significantly different (HR 0.69, 95% CI 0.45–1.06) (Kim 2020, PMID 32543684). Potency still matters in selected PCI-treated ACS: a TRITON-TIMI 38 total-event analysis found fewer recurrent primary events with prasugrel than clopidogrel (10.8% vs 15.4%; HR 0.65, 95% CI 0.46–0.92), but this analysis does not erase the parent trial's bleeding trade-off (Murphy 2008, PMID 18682445).

Older adults illustrate the competing strategy. POPular AGE randomized 1,002 patients aged ≥70 years with NSTE-ACS: clopidogrel reduced PLATO major/minor bleeding versus predominantly ticagrelor treatment (18% vs 24%; HR 0.71, 95% CI 0.54–0.94) and met noninferiority for the composite net outcome (28% vs 32%; absolute difference −4%, 95% CI −10.0 to 1.4); discontinuation was 22% versus 47%, respectively (Gimbel 2020, PMID 32334703). Thus “more potent” and “safer” are phenotype- and adherence-dependent, not universal rankings.

Open questions

  • Can dynamic, repeatedly measured ischemic and bleeding risk outperform one-time discharge scores?
  • Which patients can safely receive P2Y12 monotherapy immediately rather than after a DAPT run-in? (Mehran 2019, PMID 31556978)
  • How should antithrombotic intensity be adapted after non-atherothrombotic MI, MINOCA, or plaque erosion?
  • Does genotype- or platelet-function-guided de-escalation improve hard outcomes enough for routine use?
  • Can the COMPASS net benefit be reproduced in lower-resource populations with different bleeding detection and PPI access? (Eikelboom 2017, PMID 28844192)

References

  1. Antithrombotic Trialists' (ATT) Collaboration, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849-60. PMID 19482214
  2. Byrne RA, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44:3720-3826. PMID 37622654
  3. Mehran R, et al. Ticagrelor with or without Aspirin in High-Risk Patients after PCI. N Engl J Med. 2019;381:2032-2042. PMID 31556978
  4. Valgimigli M, et al. Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk. N Engl J Med. 2021;385:1643-1655. PMID 34449185
  5. Mauri L, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371:2155-2166. PMID 25399658
  6. Eikelboom JW, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017;377:1319-1330. PMID 28844192
  7. Virani SS, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023;148:e9-e119. PMID 37471501
  8. Rao SV, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2025;151:e771-e862. PMID 40014670
  9. Chiarito M, et al. Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI: A Prespecified TWILIGHT Substudy. JACC Cardiovasc Interv. 2022;15:282-293. PMID 35033468
  10. Dangas G, et al. Ticagrelor With or Without Aspirin After Complex PCI. J Am Coll Cardiol. 2020;75:2414-2424. PMID 32240761
  11. Chew DP, et al. Mortality From Bleeding Versus Myocardial Infarction: Loosening A Strand of the Antithrombotic Therapy "Gordian Knot". J Am Coll Cardiol. 2020;76:172-174. PMID 32646566
  12. CAPRIE Steering Committee, et al. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348:1329-39. PMID 8918275
  13. Wiviott SD, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-15. PMID 17982182
  14. Wallentin L, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-57. PMID 19717846
  15. Vranckx P, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet. 2018;392:940-949. PMID 30166073
  16. Koo BK, et al. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial. Lancet. 2021;397:2487-2496. PMID 34010616
  17. Yusuf S, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502. PMID 11519503
  18. Bonaca MP, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372:1791-800. PMID 25773268
  19. Dewilde WJ, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381:1107-15. PMID 23415013
  20. Gibson CM, et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med. 2016;375:2423-2434. PMID 27959713
  21. Cannon CP, et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med. 2017;377:1513-1524. PMID 28844193
  22. Lopes RD, et al. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. N Engl J Med. 2019;380:1509-1524. PMID 30883055
  23. Vranckx P, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet. 2019;394:1335-1343. PMID 31492505
  24. Watanabe H, et al. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial. JAMA. 2019;321:2414-2427. PMID 31237644
  25. Hahn JY, et al. Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial. JAMA. 2019;321:2428-2437. PMID 31237645
  26. Kang J, et al. Aspirin Versus Clopidogrel for Long-Term Maintenance Monotherapy After Percutaneous Coronary Intervention: The HOST-EXAM Extended Study. Circulation. 2023;147:108-117. PMID 36342475
  27. Kim BK, et al. Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial. JAMA. 2020;323:2407-2416. PMID 32543684
  28. Murphy SA, et al. Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur Heart J. 2008;29:2473-2479. PMID 18682445
  29. Gimbel M, et al. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial. Lancet. 2020;395:1374-1381. PMID 32334703